Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karl M Schumacher"'
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Autor:
Egbert, F Smit, Christophe, Dooms, Jo, Raskin, Ernest, Nadal, Lye M, Tho, Xiuning, Le, Julien, Mazieres, How, S Hin, Masahire, Morise, Viola, W Zhu, Daniel, Tan, Kristina, H Holmberg, Barbara, Ellers-Lenz, Svenja, Adrian, Sabine, Brutlach, Karl M, Schumacher, Niki, Karachaliou, Yi-Long, Wu
Publikováno v:
Future oncology (London, England). 18(9)
Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called
Autor:
Nadine Reischmann, Lorenz Pudelko, Christopher Stroh, Nina Linde, Doreen Musch, Marina Keil, Linda Pudelko, Christina Esdar, Andree Blaukat, Karl M. Schumacher, Niki Karachaliou
Publikováno v:
Cancer Research. 82:1105-1105
Background: Although advancements have been made in available targeted therapies for non-small cell lung cancer (NSCLC), most patients have an incomplete response and eventually acquire resistance. It is well known that MET signaling is a key pathway
Autor:
Andrew C. A. Wan, Benjamin C. U. Tai, Karl M. Schumacher, Annegret Schumacher, Sau Yin Chin, Jackie Y. Ying
Publikováno v:
Langmuir; Mar2008, Vol. 24 Issue 6, p2611-2617, 7p